Aytu BioPharma (AYTU) Earnings Date & Reports

Key Takeaways

• Aytu BioPharma (AYTU) will report fiscal 2027 first-quarter results after the market close on Monday, November 16, 2026.
• Wall Street consensus points to revenue of roughly $13.3 million and a net loss of about $0.26 per share for the quarter.
• EXXUA, the company's treatment for major depressive disorder (MDD), is the central story after quarterly prescriptions surged 138% sequentially in the prior quarter.
• Management expects gross margin to trough in early fiscal 2027 before recovering toward 66–67% by the fourth quarter.
• The company ended fiscal 2026 with $26.3 million in cash and guided for positive adjusted EBITDA in the second half of fiscal 2027.
• Generic competition in the ADHD (attention-deficit/hyperactivity disorder) portfolio remains a key watch item for revenue and margins.
• For deeper coverage, review the company's Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated AYTU pages.
• Explore Trending AI Robots to discover automated trading strategies across the market.

Earnings Context and Why It Matters

Aytu BioPharma operates on a July-to-June fiscal calendar, so the quarter ending September 30, 2026 represents the first quarter of fiscal 2027. This report is a key early test of whether the commercial momentum behind EXXUA, the company's recently launched antidepressant for major depressive disorder (MDD), can offset persistent erosion in its legacy ADHD franchise. In the prior quarter, EXXUA prescriptions climbed 138% sequentially and the company returned to positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). Investors will be watching whether that trajectory holds, and whether management's cost discipline continues to protect the balance sheet as it invests in a larger sales force.

Earnings Expectations

Consensus estimates call for fiscal 2027 first-quarter revenue of approximately $13.3 million, which would represent a decline of roughly 4% compared with $13.9 million in the same period a year earlier. Analysts project a net loss of about $0.26 per share, compared with a narrower loss of $0.08 per share in the prior-year quarter.

The headline figures, however, only tell part of the story. Investors will focus on EXXUA prescription growth and net revenue, which reached $3.9 million in the fourth quarter of fiscal 2026. Gross-to-net (GTN) dynamics, which reflect discounts and rebates that reduce gross revenue, are another closely watched metric. Management has guided for gross margin to be at its lowest point in early fiscal 2027 before recovering toward 66–67% by the fourth quarter, making margin trajectory a central question this quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. If you are researching pharmaceutical names or tracking AYTU alongside its peers, the AI Screener offers a practical way to surface comparable opportunities.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautiously optimistic but focused on execution. Aytu's stock has traded in a wide range as investors weigh the promise of the EXXUA launch against a shrinking legacy business. The fourth-quarter return to positive adjusted EBITDA was viewed favorably, but management has already signaled that adjusted EBITDA and operating cash flow will be lower in the first half of fiscal 2027, partly reflecting deferred sales and marketing investment of up to $6 million. Key risk factors include a slower-than-expected EXXUA prescription ramp, higher-than-expected gross-to-net deductions, and continued generic pressure on the ADHD portfolio.

Forward Outlook and Key Factors to Monitor

Beyond the reported numbers, investors should track EXXUA prescription trends closely. In the fourth quarter of fiscal 2026, total prescriptions reached 3,323, and management reported improving productivity as the sales force stabilized around 40-plus territories. Sustained script growth will be essential to offset the ADHD portfolio, where Adzenys and its authorized generic have retained roughly 80% of prescriptions despite generic competition.

Margin progression is another important theme. Management expects gross margin to bottom out in the first half of fiscal 2027 before approaching 66–67% by the fourth quarter, so any deviation from that path could shape investor expectations for the rest of the year.

Finally, watch the company's cash position and profitability guidance. Aytu ended fiscal 2026 with $26.3 million in cash and has guided for positive adjusted EBITDA during the six-month period ending June 30, 2027. Management's commentary on spending discipline, sales force expansion, and the timing of operating cash flow inflection will likely set the tone for the stock through the remainder of fiscal 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations